Literature DB >> 9114143

Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients.

J L Arredondo1, V Diaz, H Gaitan, E Maradiegue, E Oyarzún, R Paz, J L Reynal, W Stamm, D Zambrano.   

Abstract

This multicenter, prospective, double-blind study compared the safety and efficacy of clindamycin and ciprofloxacin versus ceftriaxone and doxycycline in the treatment of outpatients with mild to moderate pelvic inflammatory disease (PID) diagnosed by laparoscopy. Samples taken from the endocervix, endometrium, and abdominal cavity before treatment and from the endocervix after treatment were cultured for aerobes, anaerobes, Neisseria gonorrhoeae, and Chlamydia trachomatis. Of the 138 patients enrolled, 131 were evaluable for efficacy. The most prevalent bacteria were streptococci, staphylococci, and Escherichia coli (among aerobes) and Bacteroides species and peptostreptococci (among anaerobes). N. gonorrhoeae was present in 2% (3) of the 131 evaluable patients, and C. trachomatis was in 11% (15). The clinical cure rate was 97% (65 of 67) in the clindamycin and ciprofloxacin group and 95% (61 of 64) in the ceftriaxone and doxycycline group. Side effects were similar in both groups. In conclusion, the two regimens for the outpatient treatment of mild to moderate PID were similarly effective and safe.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9114143     DOI: 10.1093/clinids/24.2.170

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  14 in total

Review 1.  Quinolones in sexually transmitted diseases: state of the art.

Authors:  G L Ridgway
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 2.  Pelvic inflammatory disease.

Authors:  Jonathan D C Ross
Journal:  BMJ Clin Evid       Date:  2013-12-11

3.  Improvement in the clinical cure rate of outpatient management of pelvic inflammatory disease following a change in therapy.

Authors:  A Piyadigamage; J Wilson
Journal:  Sex Transm Infect       Date:  2005-06       Impact factor: 3.519

Review 4.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  Place of parenteral cephalosporins in the ambulatory setting: clinical evidence.

Authors:  D Nathwani
Journal:  Drugs       Date:  2000       Impact factor: 9.546

Review 6.  Controversies in family planning: postabortal pelvic inflammatory disease.

Authors:  Jennefer A Russo; Sharon Achilles; Teresa DePineres; Laura Gil
Journal:  Contraception       Date:  2012-05-29       Impact factor: 3.375

7.  Do short-term markers of treatment efficacy predict long-term sequelae of pelvic inflammatory disease?

Authors:  Gail M Trautmann; Kevin E Kip; Holly E Richter; David E Soper; Jeffrey F Peipert; Deborah B Nelson; Wayne Trout; Dianne Schubeck; Debra C Bass; Roberta B Ness
Journal:  Am J Obstet Gynecol       Date:  2008-01       Impact factor: 8.661

Review 8.  Pelvic inflammatory disease.

Authors:  Jonathan D C Ross
Journal:  BMJ Clin Evid       Date:  2008-03-10

Review 9.  Pelvic inflammatory disease: current concepts in pathogenesis, diagnosis and treatment.

Authors:  Caroline Mitchell; Malavika Prabhu
Journal:  Infect Dis Clin North Am       Date:  2013-10-31       Impact factor: 5.982

10.  The 1998 CDC Sexually Transmitted Diseases Treatment Guidelines.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.663

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.